The FDA’s 15-Month Curse: Why Marty Makary Became the Shortest-Lived Health Czar in a Generation

 

 The FDA’s 15-Month Curse: Why Marty Makary Became the Shortest-Lived Health Czar in a Generation

**Subtitle:** From a $23 billion vaping windfall to a 2,000-word resignation letter that never came, the battle over fruit-flavored e-cigarettes and the abortion pill has cost another health chief the job. Here is why the revolving door at the FDA is spinning faster than ever, and what it means for your drug prices and your vape pen.

**WASHINGTON** – It was supposed to be a triumphant return to normalcy. After the tumult of the COVID-19 years and the rocky tenure of his predecessor, Dr. Marty Makary—a renowned Johns Hopkins surgeon, bestselling author, and regular Fox News commentator—was confirmed as FDA commissioner in March 2025 with broad bipartisan support . He pledged to cut red tape, accelerate drug approvals, and make the agency a “beacon of innovation” again.

Fifteen months later, he is on the verge of being fired.

On Friday, May 8, 2026, multiple news outlets reported that President Donald Trump had signed off on a plan to oust Makary, following a year of mounting criticism from pharmaceutical executives, anti-abortion activists, and even Trump’s own inner circle .

The final straws were a micro-trifecta of political poison: Makary resisted approving fruit-flavored e-cigarettes—a top priority for major tobacco donors—and he was accused of “slow-walking” a review of the abortion pill mifepristone, a key demand of social conservatives ahead of the midterm elections .

The White House has not confirmed the departure, and Trump himself demurred when asked on Friday evening.

“I’ve been reading about it, but I know nothing about it,” Trump told CNN .

But the writing is on the wall. A senior administration official confirmed that Trump has “signed off,” even as aides scramble to find a replacement . The FDA is once again leaderless, and the “Make America Healthy Again” agenda is in shambles.

This article is the definitive breakdown of the fall of Marty Makary. We will dissect the political pressures that doomed him, analyze the policy flip-flops on flavored vapes, examine the quiet fury of the biotech industry, and answer the questions every American needs to know: *Who is running the FDA? And what happens to my medication approvals now?*

## Part 1: The Makary ‘Experiment’ – A Surgeon’s War on the Bureaucracy

When Makary took the job, the FDA was in crisis. During the pandemic, the agency’s reputation suffered from mixed messaging on vaccines and an exodus of senior staff. President Trump, who has always viewed the “administrative state” as an enemy of progress, wanted a disruptor .

Makary fit the bill perfectly. He was a telegenic communicator who had critiqued the medical establishment for years. He launched a podcast, “FDA Direct,” recorded in a dedicated studio at the agency’s White Oak campus . He appeared frequently on “The View” and Fox News to sell his vision.

### The ‘Kennedy’ Alliance

Crucially, Makary was a close ally of HHS Secretary Robert F. Kennedy Jr., who champions the “Make America Healthy Again” (MAHA) movement . This agenda is skeptical of Big Pharma, critical of vaccine mandates, and focused on eliminating ultra-processed foods.

Under Makary’s watch, the FDA moved aggressively on food policy. It authorized the use of natural food dyes and took steps to crack down on processed foods—moves praised by health advocates but deeply unpopular with packaged food giants .

> *“We love [Dr. Makary].”* – **Alex Clark, a Turning Point USA podcaster and MAHA advocate** .

However, his tenure was plagued by “paranoia, turmoil, and backlash” . Just as he was making enemies in the food industry, he was losing friends in the tobacco and pharmaceutical sectors.

| **MAHA Win** | **Political Fallout** |

| :--- | :--- |

| Crackdown on food dyes & ultra processed foods | Alienated packaged food lobby |

| Skepticism of rushed drug approvals | Alienated Biotech & Pharma |

| Openness to natural flavors | Set up clash with Tobacco donors |

| Ally of RFK Jr. | Became target of Pharma-backed Republicans |

## Part 2: The Vape ‘Square’ – How a $23 Billion Industry Cornered the FDA

The most immediate trigger for Makary’s ouster was the battle over **flavored e-cigarettes**.

### The Tobacco Lobby’s Wishlist

Large tobacco companies, including Altria (maker of Marlboro), have invested billions in vaping products. For years, they have lobbied the White House to allow the sale of fruit- and candy-flavored e-cigarettes, arguing they help adult smokers quit .

For months, the White House pressured Makary to authorize these flavors. According to the *Wall Street Journal*, Trump’s aides surveyed outside allies about Makary’s job performance, complaining about the lack of progress on vaping approvals .

### The March Memo (The ‘Hold’ Order)

In March 2026, the FDA issued an internal memo stating it would only approve e-cigarettes in flavors like mint, tea, and spices. The memo was explicit: fruit and candy flavors would likely be rejected because of their “appeal to young people” .

Trump was furious. According to two people familiar with the episode, the president directly pressured Makary on the issue . David Williams, president of the Taxpayers Protection Alliance, noted the shift in stance: “It’s frustrating because President Trump, during his first term, said that he wanted to move forward with approving these products, and we didn’t see that happen” .

### The Flip (The ‘Appeasement’ Reversal)

Facing termination, Makary’s FDA reversed course this week. The agency authorized fruit-flavored vapes for the first time, abruptly walking back the March guidelines.

Critics argue the reversal had little to do with science and everything to do with politics.

“FDA’s reversal may have been a way to appease Trump, rather than what [Makary] really believes for vaping,” Williams mused .

The flip saved Makary’s job for a few days, but it damaged his credibility. He was now seen as weak—a political pawn rather than a principled regulator.

| **Stakeholder** | **Wanted** | **Pressure Tactics** |

| :--- | :--- | :--- |

| **Major Tobacco Cos (Altria)** | Fruit-flavored vape approval | Campaign donations; direct lobbying of Trump |

| **President Trump** | Quick approvals; less agency “red tape” | Threat of firing; public pressure |

| **Anti-Vaping Activists** | No fruit flavors (to protect kids) | Public awareness campaigns |

| **FDA Career Staff** | Slow, science-based evaluation | Internal memos; resistance to political interference |

## Part 3: The Abortion Pill ‘Red Line’ – Social Conservatives Mobilize

While the vaping fight was about money, the fight over the abortion pill was about votes.

### The Mifepristone Mail-Order Loophole

Anti-abortion activists have long sought to reverse FDA regulations allowing providers to send mifepristone (the abortion pill) through the mail . Medication abortion now accounts for roughly **two-thirds of all US abortions**, a surge since the fall of Roe v. Wade .

Social conservatives, who form the bedrock of Trump’s base, warned that this issue could depress turnout in the 2026 midterm elections unless the administration acted decisively.

### The ‘Indifference’ Charge

Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, issued a blistering statement days before a planned White House meeting. She demanded Makary’s immediate termination.

“FDA Commissioner Makary should be fired immediately,” Dannenfelser said. “Indifference is completely unacceptable to millions of pro-life voters expecting the administration to act to save lives” .

Former Vice President Mike Pence also reportedly joined the chorus of critics, pressuring the White House to intervene .

### The Court Complication

Makary was caught in a pincer movement. The Supreme Court is expected to decide within days whether to take up a Louisiana case arguing that mail-order abortion pills undermine state laws that ban abortion .

If the Court rules against the FDA, the mail-order authorization could be struck down regardless of Makary’s actions. But conservatives wanted him to move *before* the Court acted, to show proactive leadership.

Makary’s refusal to rush a review of the safety of mifepristone (or to move definitively to restrict it) sealed his fate with the anti-abortion wing of the party .

## Part 4: The Biotech ‘Revolt’ – The Free Market Turns on the Regulator

Perhaps the most unexpected opposition came not from the left, but from the **right**—specifically, from free-market advocates who usually hate regulation.

### The ‘Failed Therapy’ Label

Under Makary, the FDA issued a series of high-profile rejection letters that infuriated biotech investors.

- **uniQure:** The FDA asked for an additional clinical trial of a gene therapy for Huntington’s disease, dashing hopes of patients. Makary’s office held a rare call with reporters defending the decision, calling the medicine a “failed therapy” .

- **Replimune:** The agency rejected a melanoma therapy, RP1, which the *Wall Street Journal* editorial board savaged in multiple opinion pieces .

- **Moderna:** The FDA initially refused to review an mRNA flu vaccine, a “complete stunner” to executives, before reversing course days later .

These decisions, many of which were upheld by career scientists, were pinned on Makary. The *Wall Street Journal* editorial page alone published over half a dozen editorials demanding his head, calling him a “roadblock” to medical innovation .

### The Share Price Indicator

On the day news of Makary’s probable ouster broke, shares of **Replimune closed nearly 22% higher** . The market’s verdict was clear: investors believed a new commissioner would be more friendly to drug approvals.

| **Biotech Company** | **FDA Action Under Makary** | **Market Reaction to Ouster News** |

| :--- | :--- | :--- |

| **Replimune** | Melanoma drug rejection (RP1) | Stock +22%  |

| **uniQure** | Phase 3 trial required for Huntington’s | Relief rally |

| **Moderna** | Initial rejection of mRNA flu vaccine | Reversal; future approvals hopeful |

## Part 5: The Turmoil – An Agency in ‘Chaos’

Makary’s potential departure has exposed a broader institutional crisis at the FDA.

### The ‘Paranoia’ Culture

Earlier in the week, *Bloomberg News* published a story titled, *“Paranoia, turmoil and backlash: Inside the FDA under Marty Makary”* . The piece described low staff morale, allegations of political interference, and fears among career scientists that their work was being overruled by political appointees.

### The Talent Drain

The agency is already bleeding talent. The CDC lacks a permanent director. The Surgeon General position is vacant. Even Makary’s close ally, top vaccine regulator Dr. Vinay Prasad, recently left under a cloud of controversy .

If Makary is fired, the FDA will be headless during a critical period, with the midterm elections looming and a potential bird flu season on the horizon.

### The Succession Mess

As of Friday evening, the White House had not finalized a replacement. Potential names being floated include former FDA commissioner Stephen Hahn and former acting commissioner Brett Giroir .

In the immediate term, Deputy Commissioner Kyle Diamantas, who heads the agency’s food group, could serve as acting commissioner .

| **Vacant Position** | **Status** |

| :--- | :--- |

| **FDA Commissioner** | Being fired (Makary) |

| **CDC Director** | No permanent replacement |

| **Surgeon General** | Vacant |

| **Top Vaccine Regulator** | Left recently (Prasad) |

## FREQUENTLY ASKING QUESTIONS (FAQs)

### Q1: Is Marty Makary officially fired yet?

**A:** Not yet. President Trump has signed off on the plan, but the termination is not final. Trump is known to change his mind at the last minute. As of Saturday, May 9, 2026, Makary remains FDA Commissioner .

### Q2: Why is Makary being fired?

**A:** Three main reasons:

1.  **Vaping:** He resisted approving fruit-flavored e-cigarettes, angering tobacco donors and the White House .

2.  **Abortion Pill:** He was accused of “slow-walking” a review of mifepristone, angering social conservatives .

3.  **Drug Approvals:** Biotech companies and the Wall Street Journal editorial board hammered him for rejecting new drugs .

### Q3. What was the final straw?

The FDA’s reversal on flavored vapes (authorizing them this week) delayed the firing but didn’t stop it. The trigger was likely the combination of the vaping controversy hitting the news cycle combined with Friday’s meeting with anti-abortion activists .

### Q4. Who is going to run the FDA now?

**A:** The White House is scrambling to find a successor. Potential names include former FDA Commissioner Stephen Hahn and Brett Giroir . Deputy Commissioner Kyle Diamantas could be named acting commissioner .

### Q5. Is this good for drug prices?

**A:** Industry investors think so. Biotech stocks rallied on the news, betting that a new commissioner will be more business-friendly and approve drugs faster .

### Q6. Is this good for vaping?

**A:** Yes. The FDA just authorized fruit-flavored e-cigarettes. A new commissioner is likely to keep the door open for further approvals .

### Q7. What was Makary’s background?

**A:** He was a surgical oncologist at Johns Hopkins, a Fox News contributor, and a bestselling author. He had no prior FDA management experience .

### Q8. How long was his tenure?

**A:** He was confirmed by the Senate in March 2025. If fired, he will have served roughly **15 months**—one of the shortest tenures for an FDA commissioner in recent decades .

## Part 6: The Midterm Factor – Why This Matters for 2026

The firing drama is not isolated to the health agency. It is a political weather vane.

### The ‘Empty Chair’ Strategy

With the midterm elections just months away, the Trump administration is now facing the prospect of entering the campaign season with a hollowed-out health department. This is a gift to Democrats, who will run ads accusing the administration of chaos and incompetence.

### The Donor Dance

The vaping reversal highlights the influence of campaign cash. Major tobacco companies have been consistent Trump donors. By forcing the approval of flavored vapes, the White House signaled that donor interests will always trump (pun intended) public health concerns.

| **Timeline** | **Event** |

| :--- | :--- |

| **March 2025** | Makary confirmed as FDA Commissioner  |

| **March 2026** | FDA memo resists fruit-flavored vapes |

| **April 2026** | Biotech complaints peak; Makary defends Replimune rejection |

| **May 8, 2026** | FDA reverses vape policy; approves fruit flavors |

| **May 8, 2026 (evening)** | WSJ/CNN report plans to fire Makary |

| **May 9, 2026 (pending)** | Potential termination/Resignation |

## CONCLUSION: The Revolving Door Spins Again

The fall of Marty Makary is a story of incompatible masters. He tried to serve the “Make America Healthy Again” movement (anti-vape, anti-junk food) while also serving the “Make America First Again” coalition (pro-business, anti-abortion).

**The Human Conclusion:** For the career scientists at the FDA, the news is demoralizing. It tells them that political loyalty matters more than scientific rigor. For the patient waiting for a rare disease drug, the news is confusing. It tells them that the approval process might speed up—or it might become even more politicized.

**The Professional Conclusion:** The revolving door at the FDA is spinning faster than ever. The agency’s independence has been eroded. Drug approval is now a political football. Whether that results in faster cures or dangerous shortcuts depends entirely on who wins the next election.

**The Viral Conclusion:**

> *“Marty Makary opposed fruit vapes. Big Tobacco donors wanted fruit vapes. Trump demanded fruit vapes. The FDA approved fruit vapes. Then they fired Makary anyway. The message: Compliance doesn’t save you. Loyalty does.”*

**The Final Line:**

The FDA is not broken; it is being remade in the image of the administration—one that prioritizes donor interests, political loyalty, and speed over science. Makary’s successor will have learned the lesson: keep the vapes flowing, and keep the pills moving.

---

*Disclaimer: This article is for informational and educational purposes only, based on reports from CNN, Reuters, the Wall Street Journal, and other sources as of May 9, 2026. The ouster has not been officially confirmed by the White House.*